In a significant development for patients battling chronic graft-versus-host disease (GVHD), the U.S. Food and Drug Administration (FDA) has granted approval to Niktimvo™ (axatilimab-csfr), a groundbreaking anti-CSF-1R antibody. This approval marks a pivotal moment in the treatment landscape, offering hope to those whose condition has persisted despite prior therapies.

Chronic GVHD, a challenging complication following allogeneic stem cell transplants, affects a substantial number of patients annually. With Niktimvo™, developed by Incyte and Syndax Pharmaceuticals, there is now a promising option targeting the inflammation and fibrosis drivers that characterize this debilitating condition. The approval follows compelling data from the AGAVE-201 study, demonstrating durable responses across various patient subgroups and organ systems.

“We are thrilled to introduce Niktimvo™ as a new frontier in the fight against chronic GVHD,” stated Hervé Hoppenot, CEO of Incyte. “This approval underscores our commitment to advancing treatments that address the urgent needs of patients and healthcare providers in managing this complex disease.”

For more detailed insights into the approval and the transformative potential of Niktimvo™, read the full announcement here.